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Abstract We developed a targeted liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method for the
site-specific quantification of lysine acetylation in the N-
terminal region of histone H4 by combining chemical deriva-
tization at the protein and peptide levels with digestion using
chymotrypsin and trypsin. Unmodified ε-amino groups were
first modified with propionic acid anhydride and the
derivatized protein digested with trypsin and chymotrypsin.
The newly formed peptide N-termini were subjected to a sec-
ond derivatization step with d6- (heavy) or d0- (light) acetic
acid anhydride. Samples were mixed at different ratios and
peptides monitored by multiple reaction monitoring (MRM)
LC-MS/MS. The method was validated in terms of linearity
(R2≥0.94), precision (RSD≤10 %), and accuracy (≤27 %)
and used to assess the effect of the histone deacetylase
(HDAC) inhibitors SAHA and MS-275 in the murine
macrophage-like cell line RAW 264.7. SAHA and MS-275
showed site-specific effects on the acetylation levels of K5
and K8 with the K5(Ac)–K8 and K5–K8(Ac) peptides
increasing 2.5-fold and 5-fold upon treatment with SAHA
and MS-275, respectively. Assessing lysine acetylation in a
site-specific manner is important for gaining a better under-
standing of the effects of HDAC inhibitors and for clarifying
disease mechanisms where lysine acetylation plays a role.
Keywords Histone acetylation . Tandemmass spectrometry .
Multiple reactionmonitoring (MRM) . Post-translation
modification (PTM) . Histone deacetylase (HDAC) inhibitors
Introduction
In eukaryotes, the basic repeating unit of chromatin is com-
posed of 147 bp of DNA wrapped around an octamer of two
molecular groups of four histone core proteins: H2A, H2B, H3,
and H4. The core histones (∼11–17 kDa) are basic proteins
with a globular domain and a flexible N-terminal extension
protruding from DNA, referred to as the N-terminal tails. The
N-terminal regions of histones are affected by different
enzyme-mediated post-translational modifications (PTMs) that
change the accessibility of DNA to transcription factors and
subsequent protein-protein interactions. In particular, acetyla-
tion of K5, K8, K12, and K16 in the N-terminal tail of histone
H4 has been described to play an important role in the epige-
netic regulation of cellular events with relevance for diseases
like cancer and Alzheimer’s disease (AD). For example, his-
tone acetylation has been shown to be crucial in hippocampal
long-term potentiation (LTP) and memory formation in mice
and both aging and AD pathology are associated with a loss of
acetylation at the N-terminal tail of histone H4 [1, 2].
Therefore, quantification of histone acetylation on individual
lysine residues is of crucial importance to understanding their
role in cell biology and disease mechanisms. Next to this, quan-
tifying histone acetylation will assist in understanding the
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effects of drugs such as histone deacetylase (HDAC) inhibitors,
many of which are currently in clinical development.
One of the challenges in quantifying the level of acetylation
at individual lysine residues in the N-terminal tail of histone
H4 is the occurrence of multiple lysines within a short stretch
of amino acids.While immunological approaches are useful to
investigate histone modification patterns, it is technically chal-
lenging to generate antibodies that can distinguish between
closely related epitopes [3]. Mass spectrometry (MS) has
emerged as a powerful method to characterize histone PTMs
complementary to antibody-based approaches [4]. Currently,
there are two complementary approaches in proteomics: the
top-down and the bottom-up approaches. In bottom-up, pro-
teins of interest are first digested with a proteolytic enzyme
and the resulting peptides analyzed by HPLC-MS/MS where-
as, in top-down, the entire protein or a large fragment thereof
is analyzed by HPLC-MS/MS [5]. While the top-down ap-
proach opens the possibility to gain an overview of different
forms of a protein due to post-translational modifications
(PTMs), it has certain limitations and presents significant chal-
lenges. Fragmentation efficiency of high molecular weight
ions is poor even though fragmentations induced by electron
capture dissociation (ECD) or electron transfer dissociation
(ETD) are more efficient than the most widely used
collision-induced dissociation (CID). Further challenges are
the fact that large precursor ions are distributed across many
charge states, reducing the overall sensitivity of the top-down
approach. The combination of the current lack of highly effi-
cient chromatographic separations for proteins when com-
pared to UHPLC of peptides and the need for high-resolution,
expensive mass spectrometers renders the top-down proteo-
mics approach less suitable for the quantitative bioanalysis of
protein modifications in complex mixtures. Nevertheless, it is
to be expected that top-down protein analysis will gain ground
with the advent of affordable high-resolution mass spectrom-
eters, more efficient protein separation techniques, and a better
understanding of the charging mechanism in electrospray ion-
ization. With the advent of multiple reaction monitoring
(MRM) for protein analysis with the bottom-up approach, it
is possible to address each modification site individually on
suitable signature peptides.
Here, we describe a targeted LC-MS/MS method for the
site-specific quantification of lysine acetylation in the N-
terminal region of histone H4 using a total histone preparation
from the murine macrophage-like cell line RAW 264.7. We
labelled at protein level the ε-amino groups of lysine residues
with propionic acid anhydride causing a mass shift of +56 Da
and protecting them from further proteolytic digestion.
Although there are many examples in the literature describing
methods for the site-specific quantification of lysine acetylation
following the scheme of labelling with propionic acid anhy-
dride and proteolytic digestion [6–8], unequivocal and direct
site-specific quantification is difficult when multiple lysines
occur in close proximity to each other in a short amino acid
sequence. In order to solve this issue, we combined the label-
ling with propionic acid anhydride at protein level with double
digestion using chymotrypsin and trypsin followed by deriva-
tization of the neo-N-termini of suitable signature peptides with
d6- (heavy) or d0- (light) acetic acid anhydride. LC-MS/MS in
the multiple reaction monitoring (MRM) mode was applied to
monitor changes in the acetylation level of individual lysine
residues upon administration of the histone deacetylase
(HDAC) inhibitors SAHA and MS-275 to RAW 264.7 cells.
Experimental section
Chemicals
Formic acid, hydrogen peroxide, chymotrypsin, trifluoroacetic
acid (TFA), d6 and d0 acetic acid anhydride, propionic acid
anhydride, ammonium hydrogencarbonate, 1.0 M
triethylamine, and 16.3Mhydroxylaminewere purchased from
Sigma-Aldrich (St. Louis, MO, USA). Trypsin was purchased
from Promega (Fitchburg, WI, USA). HPLC supra gradient
acetonitrile was obtained from Biosolve (Dieuze, France).
Triethylammonium hydrogencarbonate buffer, 1 M at pH 8.5,
was prepared by titration of a 1-M triethylamine solution with
CO2. Water was purified by a MilliQ Advantage A10 Water
System (Millipore, Billerica, MA, USA).
Cell culture and histone isolation
The murine macrophage-like cell line RAW 264.7 (American
Type Culture Collection, Manassas, VA, USA) was cultured
in Dulbecco’s modified Eagle medium (DMEM) containing
10 % heat-inactivated fetal bovine serum (FBS), 50 IU/mL
penicillin, and 50 IU/mL streptomycin at 37 °C in a humidi-
fied atmosphere containing 5 % CO2. Cell culture reagents
were purchased from Life Technologies (Carlsbad, CA,
USA). For the experiments, cells were used until passage 15.
One day after seeding, cells were treated with the HDAC
inhibi tors MS-275 (Axon Medchem, Groningen,
The Netherlands) or suberoylanilide hydroxamic acid
(SAHA, Selleckchem, Munich, Germany) (see Electronic
Supplementary Material (ESM) Fig. S1 for structures).
Inhibitor stock solutions were prepared at 10 mM for MS-
275 and 4 . 1 mM fo r SAHA, r e s p e c t i v e l y, i n
dimethylformamide (DMF), and subsequently diluted in
DMEM culture medium. Cells were incubated with 1 μM of
MS-275 or 0.41 μM of SAHA for 20 h, conditions that were
non-toxic as determined by MTS assays (ESM Figs. S2 and
S3). As a control, cells were treated with 0.01 % DMF, corre-
sponding to the same percentage used for treatment with in-
hibitors. Subsequently, cells were harvested, washed with
PBS, and pelleted by centrifugation at 1000 rpm for 5 min.
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Histones were extracted as previously described [9]. Briefly,
cell pellets were suspended in 0.5 mL ice-cold buffer contain-
ing 13 mM EDTA in 10 mM Tris-base, pH 7.4. After centri-
fugation, sulfuric acid 0.4 M was added to the pellet with
incubation of 1 h. Acetone was added to the supernatant to a
final concentration of 86 % and left at −20 °C overnight to
precipitate proteins. After centrifugation, acetone was re-
moved and the pellet, dried at room temperature, was
redissolved in phosphate-buffered saline (PBS, PAA
Laboratories GmbH, Pasching, Austria). Total protein concen-
tration was determined using the microBCA assay according
to the manufacturer’s instructions (Pierce, Rockford, USA).
Absorbance was measured with a Fluostar Optima plate read-
er (BMG, Labtech) at 580 nm. A bovine serum albumin stan-
dard (2 mg/mL; Pierce, Rockford, USA, # 23209) was used to
calibrate the assay.
Chemical derivatization of enriched histones
Tenmicrograms of enriched and dried histones was diluted with
10 μL water and treated with 2.8 μL of 1.5 % aqueous (w/v)
H2O2 for 10 min at room temperature to oxidize methionine
residues to their sulfoxides [10]. Unmodified ε-amino groups
were propionylated by adding 9 μL of propionic acid anhydride
in 60 μL of 1 M triethylammoniumhydrogencarbonate buffer,
pH 8.5. The reaction was conducted at room temperature for
10 min with mixing at 450 rpm. The obtained samples were
dried under vacuum (Eppendorf vacuum concentrator,
Hamburg , Germany) and d isso lved in 250 mM
ammoniumhydrogencarbonate, pH 8.5. Histones were digested
in two different ways: with trypsin and with a combination of
trypsin and chymotrypsin. Digestion with a combination of the
two proteases was performed by treating histones for 6 h with
7.5 μL of chymotrypsin solution (0.2 μg/μL) at 37 °C with
continuousmixing at 450 rpm and then adding 2.5μL of trypsin
solution (0.2 μg/μL) for 10 h at 37 °C. Digestion with only
trypsin was performed by treating histones with 2.5 μL of tryp-
sin solution (0.2μg/μL) for 16 h at 37 °C (mixing at 450 rpm for
all reactions). The digestions were stopped by adding 70 μL of
1 % aqueous (v/v) formic acid, and the digests were dried under
vacuum. The digests were dissolved by adding 120 μL of 1 M
triethylammoniumhydrogencarbonate at pH 8.5 followed by
acetylation of the newly formed free N-termini with 54 μL d0-
or d6- acetic acid anhydride at room temperature and mixing at
450 rpm for 10 min. The reaction was repeated three times to
assure completeness. The samples were dried and then diluted in
30 μL 250 mM ammoniumhydrogencarbonate, pH 8.5.
Propionylation or acetylation of hydroxyl-containing residues
was reversed by hydrolyzing the ester bonds with 30 μL of
0.5 mg/mL aq. hydroxylamine for 120 min at room temperature
with mixing at 450 rpm. The obtained samples were dried and
dissolved in 200 μL of 1 % (v/v) aq. formic acid. Changes in
histone H4 acetylation upon HDAC inhibitor treatment were
assessed by mixing extracted histones from untreated cells
(heavy labelled) with histones from inhibitor-treated cells (light
labelled) at a 1:1 protein ratio. Method linearity was assured by
analyzing control samples labelled with d0- or d6- acetic acid
anhydride and mixing them at the following ratios: 0:1; 0.1:1;
0.25:1; 0.5:1; 0.75:1; 1:1; 1.5:1; 2:1, and 4:1. The final volume
of all solutions was 60 μL of which 2 μL was injected for LC-
MS/MS analysis in the MRM mode.
Targeted LC-MS/MS in the MRM mode
MRM quantification was performed on a nanoAcquity UPLC
system with a reversed-phase guard column (Trap Symmetry,
C18, 100 Å, 5 μm, 300 μm×50 mm) coupled to a XEVO TQ-
S triple quadrupole mass spectrometer equipped with an
IonKey interface (Waters, Milford, MA, USA) (HSS T3,
130 Å, 1.8 μm, 150 μm×10 cm) using positive electrospray
ionization (ESI+). The vaporizer temperature of the ESI+ source
was set to 150 °C, the capillary voltage was 3.2 kV, the cone
voltage was 40 V, the source offset was 50 V, the cone gas flow
was 20 L/h, and the collision gas (argon) flow was set at
0.15 mL/min. Two microliters of sample solution was injected
with the autosampler that was kept at 10 °C and chromato-
graphically separated on the IonKey system at 40 °C at a flow
rate of 3 μL/min. Mobile phase Awas 0.1 % aq. formic acid (v/
v) and mobile phase B was 0.1 % formic acid in acetonitrile.
Gradient elution was started at 5 %mobile phase B and linearly
increased to 100 % B at a slope of 4 % B/min. For MRM
analysis, a set of two peptides comprising 8 forms correspond-
ing to different acetylation patterns were monitored for samples
digested with trypsin and chymotrypsin (ESM Table S1) and 1
peptide (16 different forms) was monitored for samples
digested only with trypsin (ESM Table S2).
To establish the MRM method, transitions for all peptide
forms were selected with the help of Skyline (MacCoss Lab,
software version 2.6.0.6851) including the following modifi-
cations: lysine propionylation and N-terminal acetylation with
d0- and d6- acetic acid anhydride. Three characteristic peptide
transitions, which allowed differentiating between different
modification sites, were monitored for each peptide form with
the dwell time set at 10ms. Themost intense singly charged y-
fragment ion was selected as quantifier. The corresponding
chromatographic peak areas were integrated with Skyline
and relative quantification based on the d0-/d6- ratio.
Results and discussion
Methodology
A schematic overview of the methodology to monitor the
lysine acetylation level in the N-terminal region of histone
H4 site-specifically is given in Fig. 1. The method starts with
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extracting histones from cell nuclei to reduce sample com-
plexity. While other nuclear proteins, such as ribosomal pro-
teins, are co-extracted, the chosen signature peptides from the
N-terminus of histone H4 were predicted to be unique. To
render our methodology suitable for monitoring the acetyla-
tion level in methionine-containing signature peptides in fu-
ture applications, we included an oxidation step with hydro-
gen peroxide in the procedure to fully oxidize methionine
residues to their corresponding sulfoxides. Methionine-
containing signature peptides are normally not preferred be-
cause they are susceptible to varying degrees of oxidation,
which may affect precision and accuracy due to poor control
of the ratio between the non-oxidized andmono-oxidized sulf-
oxide forms. To avoid such complications, we fully oxidized
the methionine residue with hydrogen peroxide to its sulfox-
ide as previously described [10]. Propionic acid anhydride has
been used as derivatization reagent to acylate amino groups at
N-termini and the -position of unmodified or mono-
methylated lysines, causing a mass shift of +56 Da and
protecting these residues from tryptic digestion. Moreover,
since the mass difference between a propionyl (+56 Da) and
the naturally occurring acetyl group on lysine residues
(+42 Da) is 14 Da, it is possible to distinguish between lysines
that were acetylated in vivo and those that were chemically
derivatized. To assure that all free primary amino groups were
fully propionylated, we repeated the propionylation step three
times [6–8]. Because of lysine propionylation, trypsin cuts
only after arginine residues resulting in a single proteolytic
fragment from the amino-terminal tail of histone H4
e n c o m p a s s i n g a l l f o u r l y s i n e r e s i d u e s
( (GKGGKGLGKGGAKR (K5–K16) ) , s equence
(sp|P62806|H4_MOUSE histone H4 OS=Mus musculus).
The challenge of site-specific quantification of lysine acetyla-
tion at the N-terminus of histone H4 is thus related to
distinguishing between the acetylation state of K5, K8, K12,
and K16. Taking all permutations into account, the total num-
ber of possible acetylated forms for this peptide is 16 (1 form
for 4K-Ac, 4 forms for 3K-Ac, 6 forms for 2K-Ac, 4 forms for
1K-Ac, and 1 form without any acetylation). However, only
some of these forms can be unambiguously quantified due to
overlapping MRM transitions (ESM Table S2). In order to
resolve this problem, we combined propionylation of lysine
residues at the protein level with proteolytic digestion using a
combination of trypsin and chymotrypsin to cleave the peptide
(GKGGKGLGKGGAKR) also after leucine. Each of the
formed peptides, GKGGKGL and GKGGAKR, contains
two lysine residues leading to four different acetylated forms
that can be quantified unambiguously because of characteris-
tic MRM transitions (ESM Table S1). In order to render the
method suitable for relative quantification, we performed a
second derivatization step after proteolytic digestion by
treating the samples with either d0- or d6- acetic acid anhy-
dride to incorporate d0- or d3-acetate at the newly formed free
N-terminal amino groups, resulting in mass additions of +42
or +45 Da, respectively.
Since acid anhydrides react also with the hydroxyl groups
of threonine, serine, and tyrosine, we treated the derivatized
samples with hydroxylamine for selective hydrolysis of ester
bonds and restoration of the free hydroxyl groups, making the
method suitable to monitor peptides bearing these residues
[11, 12]. Mixing the d0- and d6-labelled samples allowed rel-
ative quantification of each form of the signature peptides
GKGGKGL and GKGGAKR from the N-terminus of murine
histone H4.
Figure 2 shows the LC-MS/MS chromatograms of
GKGGAKR (quantifier transition (y5+) and qualifier transi-
tions (y4+, y3+) monitoring each of the four d0-forms related
to the pattern of acetylation at K12 and K16. The four forms
eluted within a time window of less than two minutes and
peptides with a higher degree of propionylation eluted at in-
creased retention times as expected [13]. Surprisingly, almost
all MRM LC-MS/MS chromatograms for different transitions
showed double peaks as shown in Fig. S4 (see ESM). Since
double peaks were also found for peptides without lysine res-
idues, we hypothesized that they originated from chemical
derivatization of the N-terminus with acetic acid anhydride
after proteolytic digestion due to racemization of the C-
terminal amino acid via oxazolone formation [14, 15] (for
more detai ls , see ESM Figs. S5 and S6 and the
accompanying text). The method may be extended to monitor
lysine acetylation in other regions of histone H4, other his-
tones, or other proteins that may be acetylated such as the
Fig. 1 Scheme of the sample preparation procedure for the site-specific
quantification of lysine acetylation in the N-terminal tail of murine
histone H4 obtained from RAW 264.7 cells
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transcription factor NF- B. It must, however, be considered
that MRM on quadrupole mass analyzers has limited mass
resolution compared to high-resolution mass analyzers (e.g.,
TOF or Orbitrap). This implies, for example, that lysine
trimethylation (+42.04 Da) cannot be distinguished from ly-
sine acetylation (+42.01 Da). Although trimethylation is not a
known modification at the N-terminus of histone H4, it may
interfere at other sites. In this case, synthetic peptides carrying
the anticipated modification will have to be used to ascertain
that the proper signature peptide is being monitored, since the
retention times of peptides containing acetylated versus
trimethylated lysine residues will differ.
Method validation
The method was validated with respect to precision and accu-
racy by mixing the (d0-/d6-)labelled histone H4-derived sig-
nature peptides at ratios ranging from 0:1 to 4:1. Regression
lines were linear across the measured range with correlation
coefficients of 0.94–0.98 (ESM Table S3), and the retention
times were similar for both d0- and d6-labelled peptides (see
ESM Fig. S4). Intra-day and inter-day precision for histone
H4-derived peptides after combined trypsin and chymotrypsin
digestion was determined at two (d0-/d6-) ratios, analyzing six
replicates within the same day or spread over three different
days. The relative standard deviation for the inter-day preci-
sion was below 0.26 % for the retention time (<0.16 s) and
below 10.1 % with respect to peak area (Tables 1 and 2).
Accuracy of the method was estimated to be better than
27 % by comparing peak areas of peptides labelled with d0-
and d6- acetic acid anhydride and mixed at a 1:1 ratio (ESM
Table S4).
Evaluation of HDAC inhibitors
MS-275 and SAHA are two structurally distinct orally ac-
tive HDAC inhibitors that are in clinical use (SAHA for
cutaneous T cell lymphoma) or are currently being studied
in clinical trials for the treatment of certain types of cancer
Fig. 2 LC-MS/MS (MRM) analysis of all four possible forms of
GKGGAKRdue to different acetylation patterns (A–D). Three transitions
were monitored for each peptide form, two qualifiers (y4+, y3+), and one
quantifier (y5+). A MRM d0-GKGGAKR; B MRM d0-GK(+
42)GGAK(+56)R; C MRM d0-GK(+56)GGAK(+42)R; D MRM
d0-GK(+42)GGAK(+42)R. Circle C enlargement of the MRM trace of
d0-GK(+56)GGAK(+42)R, which is present at lower intensity and
overlaps with the MRM trace of d0-GK(+42)GGAK(+56)R (B). Circle
D enlargement of the MRM trace of d0-GK(+42)GGAK(+42)R (D).
Black traces y5+; red traces y4+; blue traces y3+ (see Table S-1 for
details)
Table 1 Precision of peak areas
for histone H4-derived peptides
after chymotrypsin and trypsin
digestion analyzing six replicates
spread over three different days


















The levels refer to the following (d0-/d6-) mixing ratios: 0.5:1 (upper part) and 0.3:1 (lower part)
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[16], inflammation [17], viral infections [18], and neurode-
generation [19]. We applied the developed methodology to
determine the site-specific effect of MS-275 and SAHA on
the acetylation status of K5, K8, K12, and K16 in the N-
terminal region of histone H4 upon administration to RAW
264.7 murine macrophages. Macrophages play a key role in
inflammatory responses, and while the treatment of inflam-
matory diseases is a potential area of application of HDAC
inhibitors, the effect of HDAC inhibitors on the site-
specific acetylation of histones in macrophages has not
been reported. SAHA was administrated at 0.41 μM (lim-
ited by cellular toxicity) and MS-275 at 1 μM, both con-
centrations that are above the IC50 values of these inhibi-
tors for class I HDACs except for HDAC8 in the case of
MS-275 (ESM Table S5). A histone extract from untreated
cells (d6-labelled) was mixed 1:1 with an extract from treat-
ed cells (d0-labelled) and the d6- to d0- peak area ratios for
the peptides GKGGKGL (K5–K8) and GKGGAKR (K12–
K16) monitored the different peptide forms to assess chang-
es in lysine acetylation levels. Treatment of RAW264.7
cells with MS-275 and SAHA resulted in increased acety-
lation at all lysine residues (Fig. 3). Treatment with MS-
275 led to a 5-fold increase in acetylation at K5(Ac)–K8
and K5–K8(Ac), respectively, while this increase was about
2.5-fold for SAHA. Acetylation of K12(Ac)–K16 and
K12–K16(Ac) was increased by approximately 2–2.5-fold
for both inhibitors (p<0.05). The fully acetylated forms
were not detected.
The higher level of K5(Ac)–K8 and K5–K8(Ac) for MS-
275-treated cells is in agreement with previous findings, albeit
in different cells, indicating that treatment with this inhibitor
leads to more robust hyper-acetylation than that with SAHA
[20, 21].
Fig. 3 Effect of the HDAC inhibitors MS-275 (1 μM) and SAHA
(0.41 μM) on lysine acetylation in the N-terminal tail of murine histone
H4 upon administration to RAW264.7 cells. 0.01 % DMF was included
as control to mimic the effect of the solvent on histone acetylation.
Acetylated lysine residues are indicated (Ac). The standard deviation
relates to three independent biological replicates each analyzed twice.
Statistically significant differences (p < 0.05) were found when
comparing each monitored form of MS-275- and SAHA-treated sample
with the corresponding forms from the DMF-treated sample (MS-275-
DMF and SAHA-DMF) and comparing each form between the two
inhibitor-treated cells (MS-275-SAHA); see ESM Table S6 for more
details on how the peak areas were calculated with the corresponding
statistical parameters
Table 2 Precision of retention
times for histone H4-derived
peptides after chymotrypsin and
trypsin digestion analyzing six
replicates spread over three
different days


















The levels refer to the following (d0-/d6-) mixing ratios: 0.5:1 (upper part) and 0.3:1 (lower part)
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Conclusions
The analytical strategy of chemical derivatization at the pro-
tein and peptide levels, combined with digestion using chy-
motrypsin and trypsin, allows differentiating between the acet-
ylation levels at individual lysine residues. We demonstrate
the utility of this method by analyzing changes in the lysine
acetylation profile of the N-terminal region of histone H4
upon treatment of RAW 264.7 cells with the HDAC inhibitors
MS-275 and SAHA showing that MS-275 results in signifi-
cantly higher levels of acetylation at K5(Ac)–K8 and K5–
K8(Ac) than SAHA. The described methodology may be
adapted to monitor site-specific lysine acetylation changes in
other histones as well as in non-histone proteins.
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